• 1
    O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010; 51: 30728.
  • 2
    Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 275869.
  • 3
    Sandahl TD, Jepsen P, Thomsen KL, et al. Incidence and mortality of alcoholic hepatitis in Denmark 1999–2008: a nationwide population based cohort study. J Hepatol 2011; 54: 7604.
  • 4
    Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193.
  • 5
    Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 25560.
  • 6
    Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol 2012; 56(Suppl. 1): S3945.
  • 7
    EASL. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399420.
  • 8
    Coffin PO, Sharpe BA. Cause of death in alcoholic hepatitis. J Hosp Med 2007; 2: 512.
  • 9
    Yu CH, Xu CF, Ye H, et al. Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials. World J Gastroenterol 2010; 16: 2435.
  • 10
    Verma S, Ajudia K, Mendler M, et al. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006; 51: 163743.
  • 11
    Epstein FH, Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 146776.
  • 12
    McClain CJ. Tumor necrosis and alcoholic hepatitis. Hepatology 1991; 14: 3946.
  • 13
    Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 13907.
  • 14
    Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multi-center trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953.
  • 15
    Semmler J, Gebert U, Eisenhut T, et al. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 1993; 78: 5205.
  • 16
    McHutchison JG, Runyon BA, Draguesku JO, et al. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991; 14: 96A.
  • 17
    Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; 4: CD007339.
  • 18
    Humaidan P, Polyzos NP. (Meta)analyze this: systematic reviews might lose credibility. Nat Med 2012; 18: 1321.
  • 19
    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
  • 20
    Cochrane Handbook. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG On behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, eds. Cochrane Handbook. London: John Wiley and Sons (under Cochrane books imprint), 2008.
  • 21
    Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010; 8: 18.
  • 22
    Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med 2008; 5: e20.
  • 23
    Raj AS, MacDonald GA. Does the addition of prednisone to pentoxifylline improve outcome in severe alcoholic hepatitis? J Gastroenterol Hepatol 2011; 26(Suppl. 4): 44.
  • 24
    Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48: 46570.
  • 25
    De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 15: 1613.
  • 26
    García JRG, Hernández GS, López AM, et al. Pentoxifilina versus esteroide en la sobrevivencia a corto plazo en hepatitis aguda alcohólica severa. Medicina Interna de México 2012; 28: 228.
  • 27
    Kim DJ, Suk KT, Park SH, Lee HJ, KASL ASG. Interim report: Short-term survival in patients with severe alcoholic hepatitis treated with corticosteroid vs. pentoxifylline: a non-inferiority trial. 대한간학회지2011. Available at: Accessed April 1, 2013.
  • 28
    Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short term survival in severe alcoholic hepatitis: a double blind, placebo controlled trial. Gastroenterology 2000; 119: 163748.
  • 29
    Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 175562.
  • 30
    Sidhu SS, Goyal O, Singla P, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012; 57: 166471.
  • 31
    Paladugu H, Sawant P, Dalvi L, et al. Role of pentoxifylline in treatment of severe acute alcoholic hepatitis – a randomized controlled trial. J Gastroenterol Hepatol 2006; 21: A459.
  • 32
    Sidhu S, Singla M, Bhatia K. Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Hepatology 2006; 44(Suppl. 1): 373A.
  • 33
    Mathurin P. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: results of the Corpentox trial. Hepatology 2011; 54(Suppl. 1): 81A.
  • 34
    Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 134854.
  • 35
    Louvet A, Dao TM, Nahon P, et al. Pentoxifylline does not improve short-term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomised controlled trial. J Hepatol 2012; 56: S533.
  • 36
    International Club of Ascites Guidelines. Available at: Accessed January, 22 2013.
  • 37
    STOPAH trial. Available at: Accessed January 22, 2013.